Trial Profile
A Phase Ib/II study of Savolitinib in non-small cell lung cancer patients with c-Met mutations.
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 21 Sep 2022
Price :
$35
*
At a glance
- Drugs Savolitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Aug 2016 New trial record